Mersana Therapeutics, Inc. is a biotechnology company. It focused on discovering and developing a pipeline of antibody drug conjugates. The company's product candidates include XMT-1522 and XMT-1536 which are in clinical stage. Mersana Therapeutics, Inc. is based in CAMBRIDGE, United States.
| Revenue (Most Recent Fiscal Year) | $40.50M |
| Net Income (Most Recent Fiscal Year) | $-69.19M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 1.28 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -216.41% |
| Net Margin (Trailing 12 Months) | -217.63% |
| Return on Equity (Trailing 12 Months) | -990.16% |
| Return on Assets (Trailing 12 Months) | -48.87% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.83 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.83 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 13.35 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $-0.25 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.19 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.56 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.59 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 124.63M |
| Free Float | 108.43M |
| Market Capitalization | $43.50M |
| Average Volume (Last 20 Days) | 2.93M |
| Beta (Past 60 Months) | 1.32 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 13.00% |
| Percentage Held By Institutions (Latest 13F Reports) | 93.92% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |